ArticleEuropean journal of nuclear medicine and molecular imaging2025
Fibroblast activation protein-targeted PET/CT in multiple non-ischemic cardiomyopathies.
Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectivesFibroblast activation protein (FAP)-targeted PET/CT can visualize activated fibroblasts, offering us the opportunity to identify myocardial fibrosis at an early stage. We aimed to establish a preliminary mapping of [68Ga]Ga-FAPI PET/CT in patients with non-ischemic cardiomyopathy (NICM), and to explore the correlation between myocardial FAPI uptake and cardiac function.
methodsFifty patients with different subtypes of NICM were enrolled. All patients underwent [68Ga]Ga-FAPI-04 PET/CT. A positive PET scan was defined as increased left ventricular (LV) FAPI activity than blood pool. LV molecular volume (LVMV), SUVr and SUVmean were calculated using a semi-automatic quantification method. The correlations between FAPI-uptake values and ventricular function were analyzed.
resultsAmong all patients, 64% (32/50) exhibited a positive PET scan, with 16 patients demonstrating with patchy uptake and another 16 patients displaying with extensive uptake. LVMV, SUVr, and SUVmean were significantly higher in patients with extensive uptake than those with patchy uptake [LVMV, 254.5 (107.7–404.0) vs. 20.9 (4.5–31.3), p < 0.0001; SUVr, 4.7 (3.2–6.7) vs. 2.3 (2.0–3.0), p = 0.0003; SUVmean, 2.8 (2.2–3.5) vs. 2.1 (1.6–2.4), p = 0.0147]. Notably, [68Ga]Ga-FAPI uptake values significantly correlated with N-terminal pro–brain natriuretic peptide (NT-proBNP), and abnormal LV contractile function assessed by echocardiography, including LV ejection fraction, LV end-diastolic dimension, and LV end-diastolic dimension (p < 0.05). In subgroup analysis focusing on patients with dilated cardiomyopathy (n = 13), the correlation between [68Ga]Ga-FAPI uptake and echocardiographic parameters was also observed (p < 0.05).
conclusions[68Ga]Ga-FAPI PET/CT demonstrated diverse myocardial fibroblast activation in NICM, which correlated with impaired ventricular contractile function and elevated NT-proBNP levels. These findings highlight its potential as a valuable imaging tool for early disease detection and risk stratification in NICM.
Indexed as
Identifiers
40504387What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.